News | January 12, 2022
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
Ind-Ra expects revenue growth of over 12% in 2022.
Ind-Ra expects revenue growth of over 12% in 2022.
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
The list of kids with co-morbidities eligible for vaccination would be announced by the government
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
The medicine is now approved for eight indications across five different types of cancer in China.
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Subscribe To Our Newsletter & Stay Updated
